Abstract Body

Biological sex confers specific immunologic advantages and challenges to both men and women. These differences lead to distinct patterns of immune responses and differing susceptibility to infections and to autoimmune and inflammatory pathology. There are data demonstrating sex-specific features of HIV acquisition, pathogenesis and the dynamics of the HIV reservoir, but many open questions remain. Despite the high burden of HIV infection among women, estimated at more than 50% of adults in 2018, enrollment of both cis and transgender women in clinical trials and basic research cohorts has been variable. In some domains, a notable lack of representation undermines the confidence that the data can be applied to all people living with HIV infection. However, sex differences represent a rich source for discovery. A comparative biology approach can leverage differences in immune responses and viral control to highlight pathways critical for vaccine development, cure interventions, or prevention of inflammatory comorbidity for both men and women. This same lens can be used to better understand the health risks and specific clinical needs for transgender men and women. Further, insuring that interventions are efficacious in women as well as men is essential to achieve the global goals for prevention, treatment and reduction in morbidity. To address these questions, both women and men must be enrolled in studies and the impact of both sex and gender assessed. This mandate to study both sexes is compelling from a scientific rigor and discovery perspective, and also meets our ethical responsibility to insure our innovations will work for all people living with HIV.